Spruce Biosciences Inc (SPRB) 13F Ownership Report (Q2 2026)

SPRB ranks #5562 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

SPRB is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

64 institutions disclose a position in SPRB, but none treat it as a major bet — even AIGH Capital Management LLC, its most concentrated holder, allocates just 0.8% of its own portfolio to it.

Morgan Stanley has added to its SPRB position for two straight quarters, increasing it by $204.4K to reach $238.2K today.

Ikarian Capital, LLC has trimmed its SPRB position for two straight quarters, cutting it by $4.0M while still holding $6.6M.

SPRB is down 5.7% today, but institutions show net buying of $73.4M this quarter — a divergence between today's price move and the underlying institutional flow.

SPRB reported a net loss of $51.4M over the trailing twelve months.

• Not yet profitable — net loss of $51.4M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$48.3M to -$51.4M
• Operating cash flow was negative, using $33.3M in cash
• Current ratio of 5.17x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.25x equity — within a conventional range